Includes: | complications of medical devices
correct drug properly administered in therapeutic or prophylactic dosage as the cause of any adverse effect misadventures to patients during surgical and medical care surgical and medical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure |
|||||||
Excludes: | accidental overdose of drug or wrong drug given or taken in error
|
Note: | For list of specific drugs classified under the fourth-character subdivisions, see Table of drugs and chemicals in Alphabetical Index. | |||||||
Excludes: | accidents in the technique of administration of drugs, medicaments and biological substances in medical and surgical procedures
|
Y40 | Systemic antibiotics | |||||||
Excludes: | antibiotics, topically used
antineoplastic antibiotics |
|||||||
Y40.0 | Penicillins | |||||||
Y40.1 | Cefalosporins and other beta-lactam antibiotics | |||||||
Y40.2 | Chloramphenicol group | |||||||
Y40.3 | Macrolides | |||||||
Y40.4 | Tetracyclines | |||||||
Y40.5 | Aminoglycosides | |||||||
Streptomycin
|
||||||||
Y40.6 | Rifamycins | |||||||
Y40.7 | Antifungal antibiotics, systemically used | |||||||
Y40.8 | Other systemic antibiotics | |||||||
Y40.9 | Systemic antibiotic, unspecified |
Y41 | Other systemic anti-infectives and antiparasitics | |||||||
Excludes: | anti-infectives, topically used
|
|||||||
Y41.0 | Sulfonamides | |||||||
Y41.1 | Antimycobacterial drugs | |||||||
Excludes: | rifamycins
streptomycin |
|||||||
Y41.2 | Antimalarials and drugs acting on other blood protozoa | |||||||
Excludes: | hydroxyquinoline derivatives
|
|||||||
Y41.3 | Other antiprotozoal drugs | |||||||
Y41.4 | Anthelminthics | |||||||
Y41.5 | Antiviral drugs | |||||||
Excludes: | amantadine
cytarabine |
|||||||
Y41.8 | Other specified systemic anti-infectives and antiparasitics | |||||||
Hydroxyquinoline derivatives
|
||||||||
Excludes: | antimalarial drugs
|
|||||||
Y41.9 | Systemic anti-infective and antiparasitic, unspecified |
Y42 | Hormones and their synthetic substitutes and antagonists, not elsewhere classified | |||||||
Excludes: | mineralocorticoids and their antagonists
oxytocic hormones parathyroid hormones and derivatives |
|||||||
Y42.0 | Glucocorticoids and synthetic analogues | |||||||
Excludes: | glucocorticoids, topically used
|
|||||||
Y42.1 | Thyroid hormones and substitutes | |||||||
Y42.2 | Antithyroid drugs | |||||||
Y42.3 | Insulin and oral hypoglycaemic [antidiabetic] drugs | |||||||
Y42.4 | Oral contraceptives | |||||||
Multiple- and single-ingredient preparations
|
||||||||
Y42.5 | Other estrogens and progestogens | |||||||
Mixtures and substitutes
|
||||||||
Y42.6 | Antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified | |||||||
Tamoxifen
|
||||||||
Y42.7 | Androgens and anabolic congeners | |||||||
Y42.8 | Other and unspecified hormones and their synthetic substitutes | |||||||
Anterior pituitary [adenohypophyseal] hormones
|
||||||||
Y42.9 | Other and unspecified hormone antagonists |
Y43 | Primarily systemic agents | |||||||
Excludes: | vitamins NEC
|
|||||||
Y43.0 | Antiallergic and antiemetic drugs | |||||||
Excludes: | phenothiazine-based neuroleptics
|
|||||||
Y43.1 | Antineoplastic antimetabolites | |||||||
Cytarabine
|
||||||||
Y43.2 | Antineoplastic natural products | |||||||
Y43.3 | Other antineoplastic drugs | |||||||
Antineoplastic antibiotics
|
||||||||
Excludes: | tamoxifen
|
|||||||
Y43.4 | Immunosuppressive agents | |||||||
Y43.5 | Acidifying and alkalizing agents | |||||||
Y43.6 | Enzymes, not elsewhere classified | |||||||
Y43.8 | Other primarily systemic agents, not elsewhere classified | |||||||
Heavy-metal antagonists
|
||||||||
Y43.9 | Primarily systemic agent, unspecified |
Y44 | Agents primarily affecting blood constituents | |||||||
Y44.0 | Iron preparations and other anti-hypochromic-anaemia preparations | |||||||
Y44.1 | Vitamin B 12 , folic acid and other anti-megaloblastic-anaemia preparations | |||||||
Y44.2 | Anticoagulants | |||||||
Y44.3 | Anticoagulant antagonists, vitamin K and other coagulants | |||||||
Y44.4 | Antithrombotic drugs [platelet-aggregation inhibitors] | |||||||
Excludes: | acetylsalicylic acid
dipyridamole |
|||||||
Y44.5 | Thrombolytic drugs | |||||||
Y44.6 | Natural blood and blood products | |||||||
Excludes: | immunoglobulin
|
|||||||
Y44.7 | Plasma substitutes | |||||||
Y44.9 | Other and unspecified agents affecting blood constituents |
Y45 | Analgesics, antipyretics and anti-inflammatory drugs | |||||||
Y45.0 | Opioids and related analgesics | |||||||
Y45.1 | Salicylates | |||||||
Y45.2 | Propionic acid derivatives | |||||||
Propanoic acid derivatives
|
||||||||
Y45.3 | Other nonsteroidal anti-inflammatory drugs [NSAID] | |||||||
Y45.4 | Antirheumatics | |||||||
Excludes: | chloroquine
glucocorticoids salicylates |
|||||||
Y45.5 | 4-Aminophenol derivatives | |||||||
Y45.8 | Other analgesics and antipyretics | |||||||
Y45.9 | Analgesic, antipyretic and anti-inflammatory drug, unspecified |
Y46 | Antiepileptics and antiparkinsonism drugs | |||||||
Excludes: | acetazolamide
barbiturates NEC benzodiazepines paraldehyde |
|||||||
Y46.0 | Succinimides | |||||||
Y46.1 | Oxazolidinediones | |||||||
Y46.2 | Hydantoin derivatives | |||||||
Y46.3 | Deoxybarbiturates | |||||||
Y46.4 | Iminostilbenes | |||||||
Carbamazepine
|
||||||||
Y46.5 | Valproic acid | |||||||
Y46.6 | Other and unspecified antiepileptics | |||||||
Y46.7 | Antiparkinsonism drugs | |||||||
Amantadine
|
||||||||
Y46.8 | Antispasticity drugs | |||||||
Excludes: | benzodiazepines
|
Y47 | Sedatives, hypnotics and antianxiety drugs | |||||||
Y47.0 | Barbiturates, not elsewhere classified | |||||||
Excludes: | deoxybarbiturates
thiobarbiturates |
|||||||
Y47.1 | Benzodiazepines | |||||||
Y47.2 | Cloral derivatives | |||||||
Y47.3 | Paraldehyde | |||||||
Y47.4 | Bromine compounds | |||||||
Y47.5 | Mixed sedatives and hypnotics, not elsewhere classified | |||||||
Y47.8 | Other sedatives, hypnotics and antianxiety drugs | |||||||
Methaqualone
|
||||||||
Y47.9 | Sedative, hypnotic and antianxiety drug, unspecified | |||||||
Sleeping:
|
||||||||
· draught
· drug · tablet |
}
} } |
NOS
|
Y49 | Psychotropic drugs, not elsewhere classified | |||||||
Excludes: | appetite depressants [anorectics]
barbiturates NEC benzodiazepines caffeine cocaine methaqualone |
|||||||
Y49.0 | Tricyclic and tetracyclic antidepressants | |||||||
Y49.1 | Monoamine-oxidase-inhibitor antidepressants | |||||||
Y49.2 | Other and unspecified antidepressants | |||||||
Y49.3 | Phenothiazine antipsychotics and neuroleptics | |||||||
Y49.4 | Butyrophenone and thioxanthene neuroleptics | |||||||
Y49.5 | Other antipsychotics and neuroleptics | |||||||
Excludes: | rauwolfia
|
|||||||
Y49.6 | Psychodysleptics [hallucinogens] | |||||||
Y49.7 | Psychostimulants with abuse potential | |||||||
Y49.8 | Other psychotropic drugs, not elsewhere classified | |||||||
Y49.9 | Psychotropic drug, unspecified |
Y50 | Central nervous system stimulants, not elsewhere classified | |||||||
Y50.0 | Analeptics | |||||||
Y50.1 | Opioid receptor antagonists | |||||||
Y50.2 | Methylxanthines, not elsewhere classified | |||||||
Caffeine
|
||||||||
Excludes: | aminophylline
theobromine theophylline |
|||||||
Y50.8 | Other central nervous system stimulants | |||||||
Y50.9 | Central nervous system stimulant, unspecified |
Y51 | Drugs primarily affecting the autonomic nervous system | |||||||
Y51.0 | Anticholinesterase agents | |||||||
Y51.1 | Other parasympathomimetics [cholinergics] | |||||||
Y51.2 | Ganglionic blocking drugs, not elsewhere classified | |||||||
Y51.3 | Other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, not elsewhere classified | |||||||
Papaverine
|
||||||||
Y51.4 | Predominantly alpha-adrenoreceptor agonists, not elsewhere classified | |||||||
Metaraminol
|
||||||||
Y51.5 | Predominantly beta-adrenoreceptor agonists, not elsewhere classified | |||||||
Excludes: | salbutamol
|
|||||||
Y51.6 | Alpha-adrenoreceptor antagonists, not elsewhere classified | |||||||
Excludes: | ergot alkaloids
|
|||||||
Y51.7 | Beta-adrenoreceptor antagonists, not elsewhere classified | |||||||
Y51.8 | Centrally acting and adrenergic-neuron-blocking agents, not elsewhere classified | |||||||
Excludes: | clonidine
guanethidine |
|||||||
Y51.9 | Other and unspecified drugs primarily affecting the autonomic nervous system | |||||||
Drugs stimulating both alpha- and beta-adrenoreceptors
|
Y52 | Agents primarily affecting the cardiovascular system | |||||||
Excludes: | metaraminol
|
|||||||
Y52.0 | Cardiac-stimulant glycosides and drugs of similar action | |||||||
Y52.1 | Calcium-channel blockers | |||||||
Y52.2 | Other antidysrhythmic drugs, not elsewhere classified | |||||||
Excludes: | beta-adrenoreceptor antagonists
|
|||||||
Y52.3 | Coronary vasodilators, not elsewhere classified | |||||||
Dipyridamole
|
||||||||
Excludes: | beta-adrenoreceptor antagonists
calcium-channel blockers |
|||||||
Y52.4 | Angiotensin-converting-enzyme inhibitors | |||||||
Y52.5 | Other antihypertensive drugs, not elsewhere classified | |||||||
Clonidine
Guanethidine Rauwolfia |
||||||||
Excludes: | beta-adrenoreceptor antagonists
calcium-channel blockers diuretics |
|||||||
Y52.6 | Antihyperlipidaemic and antiarteriosclerotic drugs | |||||||
Y52.7 | Peripheral vasodilators | |||||||
Nicotinic acid (derivatives)
|
||||||||
Excludes: | papaverine
|
|||||||
Y52.8 | Antivaricose drugs, including sclerosing agents | |||||||
Y52.9 | Other and unspecified agents primarily affecting the cardiovascular system |
Y53 | Agents primarily affecting the gastrointestinal system | |||||||
Y53.0 | Histamine H 2 -receptor antagonists | |||||||
Y53.1 | Other antacids and anti-gastric-secretion drugs | |||||||
Y53.2 | Stimulant laxatives | |||||||
Y53.3 | Saline and osmotic laxatives | |||||||
Y53.4 | Other laxatives | |||||||
Intestinal atonia drugs
|
||||||||
Y53.5 | Digestants | |||||||
Y53.6 | Antidiarrhoeal drugs | |||||||
Excludes: | systemic antibiotics and other anti-infectives
|
|||||||
Y53.7 | Emetics | |||||||
Y53.8 | Other agents primarily affecting the gastrointestinal system | |||||||
Y53.9 | Agent primarily affecting the gastrointestinal system, unspecified |
Y55 | Agents primarily acting on smooth and skeletal muscles and the respiratory system | |||||||
Y55.0 | Oxytocic drugs | |||||||
Ergot alkaloids
|
||||||||
Excludes: | estrogens, progestogens and antagonists
|
|||||||
Y55.1 | Skeletal muscle relaxants [neuromuscular blocking agents] | |||||||
Excludes: | antispasticity drugs
|
|||||||
Y55.2 | Other and unspecified agents primarily acting on muscles | |||||||
Y55.3 | Antitussives | |||||||
Y55.4 | Expectorants | |||||||
Y55.5 | Anti-common-cold drugs | |||||||
Y55.6 | Antiasthmatics, not elsewhere classified | |||||||
Aminophylline
Salbutamol Theobromine Theophylline |
||||||||
Excludes: | beta-adrenoreceptor agonists
anterior pituitary [adenohypophyseal] hormones |
|||||||
Y55.7 | Other and unspecified agents primarily acting on the respiratory system |
Y57 | Other and unspecified drugs and medicaments | |||||||
Y57.0 | Appetite depressants [anorectics] | |||||||
Y57.1 | Lipotropic drugs | |||||||
Y57.2 | Antidotes and chelating agents, not elsewhere classified | |||||||
Y57.3 | Alcohol deterrents | |||||||
Y57.4 | Pharmaceutical excipients | |||||||
Y57.5 | X-ray contrast media | |||||||
Y57.6 | Other diagnostic agents | |||||||
Y57.7 | Vitamins, not elsewhere classified | |||||||
Excludes: | nicotinic acid
vitamin B 12 vitamin D vitamin K |
|||||||
Y57.8 | Other drugs and medicaments | |||||||
Y57.9 | Drug or medicament, unspecified |